Validation of a Psycho-Sensory hAllucinations Scale (PSAS) in schizophrenia and Parkinson’s disease.
Schizophrenia Research. 2015-02-01; 161(2-3): 269-276
DOI: 10.1016/j.schres.2014.11.010
Lire sur PubMed
1. Schizophr Res. 2015 Feb;161(2-3):269-76. doi: 10.1016/j.schres.2014.11.010.
Epub 2014 Dec 4.
Validation of a Psycho-Sensory hAllucinations Scale (PSAS) in schizophrenia and
Parkinson’s disease.
de Chazeron I(1), Pereira B(2), Chereau-Boudet I(3), Brousse G(4), Misdrahi
D(5), Fénelon G(6), Tronche AM(7), Schwan R(8), Lançon C(9), Marques A(10),
Debilly B(11), Durif F(12), Llorca PM(13).
Author information:
(1)Univ Clermont 1, UFR Medecine, EA7280, Clermont-Ferrand F-63001 France; CHU
Clermont-Ferrand, Psychiatry B, Clermont-Ferrand F-63003, France. Electronic
address: .
(2)CHU Clermont-Ferrand, Biostatistics Unit (DRCI), Clermont-Ferrand F-63003,
France. Electronic address: .
(3)Univ Clermont 1, UFR Medecine, EA7280, Clermont-Ferrand F-63001, France; CHU
Clermont-Ferrand, Psychiatry B, Clermont-Ferrand F-63003, France. Electronic
address: .
(4)Univ Clermont 1, UFR Medecine, EA7280, Clermont-Ferrand F-63001, France; CHU
Clermont-Ferrand, Psychiatry B, Clermont-Ferrand F-63003, France. Electronic
address: .
(5)Pôle de Psychiatrie Adulte, CH Charles Perrens, cs 81285, 33000 Bordeaux
cedex, France; CNRS UMR 5287-INCIA-« Neuroimagerie et cognition humaine »,
Université Bordeaux 2, Bordeaux, France. Electronic address:
.
(6)AP-HP, Groupe Hospitalier Henri-Mondor, Service de neurologie, Créteil,
France; INSERM U955, Equipe 1, Institut Mondor de Recherche Biomédicale,
Créteil, France; Ecole Normale Supérieure, Institut d’Etudes Cognitives, Paris,
France. Electronic address: .
(7)CHU Clermont-Ferrand, Psychiatry B, Clermont-Ferrand F-63003, France.
Electronic address: .
(8)Pole hospitalier universitaire de psychiatrie du Grand Nancy, CPN, France;
Chef de Service Maison des Addictions, CHU de Nancy, France. Electronic address:
.
(9)EA 3279-Public Health, Chronic Disease, and Quality of Life Research Unit,
Aix-Marseille University, 13005 Marseille, France; Department of Psychiatry,
Sainte-Marguerite University Hospital, 13009 Marseille, France; Department of
Addiction, Sainte-Marguerite University Hospital, 13009 Marseille, France.
Electronic address: .
(10)Univ Clermont 1, UFR Medecine, EA7280, Clermont-Ferrand F-63001, France; CHU
Clermont-Ferrand, Neurology A, Clermont-Ferrand F-63003, France. Electronic
address: .
(11)Univ Clermont 1, UFR Medecine, EA7280, Clermont-Ferrand F-63001, France; CHU
Clermont-Ferrand, Neurology A, Clermont-Ferrand F-63003, France. Electronic
address: .
(12)Univ Clermont 1, UFR Medecine, EA7280, Clermont-Ferrand F-63001, France; CHU
Clermont-Ferrand, Neurology A, Clermont-Ferrand F-63003, France. Electronic
address: .
(13)Univ Clermont 1, UFR Medecine, EA7280, Clermont-Ferrand F-63001, France; CHU
Clermont-Ferrand, Psychiatry B, Clermont-Ferrand F-63003, France. Electronic
address: .
OBJECTIVE: If hallucinations are the most common of schizophrenic symptoms, they
have been described in other pathologies such as Parkinson’s disease (PD) but
may differ considerably in their phenomenology. However, no multi-modal clinical
scale with a transnosographic approach has been developed today. The purpose of
this study was to create and validate a new tool for the hetero-assessment of
all sensory modalities of hallucinations schizophrenia (SCZ) and in PD.
METHOD: Scale items were generated by literature review and validated by medical
board. A study was then made to evaluate psychometric properties of the
Psycho-Sensory hAllucinations Scale (PSAS) that include four domains (auditory,
visual, olfactory and gustatory, cenesthetic modalities) and one specific item
‘guardian angel’.
RESULTS: It was then validated in 137 patients: 86 PD (53.5% male; mean
age=53.3years) and 51 SCZ (64.7% male; mean age=38.5years). Factorial analysis
of the PSAS found four factors. The PSAS showed good internal consistency
[Kuder-Richardson alpha coefficient 0.49 to 0.77] and good test-retest
reliability [Agreement %=0.75 to 0.97] and inter-rater reliability [Agreement
%=0.78 to 1.0]. The convergent validity illustrates the concomitant evaluation
of the concept between PSAS and PANSS P3 and UPDRS1 I2.
CONCLUSION: The PSAS can be useful to describe the whole hallucination and its
evolution during the course of the disease and treatment in schizophrenia and
PD. Moreover, it can allow us to undertake a clinic-pathological comparison of
hallucination modalities between these two diseases, to enhance our
understanding of their precise neurological mechanisms.
Copyright © 2014 Elsevier B.V. All rights reserved.
DOI: 10.1016/j.schres.2014.11.010
PMID: 25481345 [Indexed for MEDLINE]